# Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

> **NCT00195286** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 180 (actual)

## Conditions studied

- Urinary Infections

## Interventions

- **DRUG:** piperacillin/tazobactam

## Key facts

- **NCT ID:** NCT00195286
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2009-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195286, "Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00195286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*